Navigation Links
Prostate cancer treatment study changing the way doctors practice
Date:4/4/2013

A study published today in the New England Journal of Medicine recommends a dramatic shift in the way doctors treat metastatic prostate cancer.

"These results have changed the way I treat patients," said Ian M. Thompson Jr., M.D., director of the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio and senior author on the international study.

Hormone therapy in hormone-sensitive prostate cancer has been shown to help extend the lives of patients, but it causes a range of unpleasant side effects in men like moodiness, hot flashes, bone loss and sexual dysfunction. To give patients relief, doctors have, in some cases, "pulsed" the therapy giving it to men for a time and then stopping it until the signs of prostate cancer activity reappear, then starting the hormone therapy again until the cancer appears to be under control.

The study shows that the continuous therapy helps men more. Men with less advanced metastatic prostate cancer who received the "pulse" or intermittent hormone therapy died an average of two years sooner than those on continuous therapy. The study results first drew attention when they were announced last summer at the annual meeting of the American Society of Clinical Oncology.

After that, prostate cancer survivor Floyd Balter switched from pulse to continuous therapy.

"Last year Dr. Thompson told me about the study results," said Balter, 78. "I said, 'Let's do it.'"

Surviving 17 years beyond a diagnosis where he'd been given two years to live, Balter said he's determined to watch his grandchildren grow for as long as possible.

"I want to live as long as I can," he said. "I can live with the side effects. They're a pain but I can tolerate them."

In the study results, if men with more extensive disease are included in the group, survival was more modest, extended by an average of 7 months, "which is longer than any other intervention," said Dr. Thompson, director of the CTRC. Often advances in cancer treatments will only extend life by an average of two or three months, he noted.

"I can now give a patient the option of putting up with some side effects in order to spend several more months or even years with his grandchildren," Dr. Thompson said. "I can tell you they are happy to have that choice."

Also, Dr. Thompson pointed out, because of the increase in PSA testing, most men who are diagnosed with metastatic prostate cancer present with disease that is still minimal.

The study followed 1,535 men with metastatic prostate cancer for a median of almost 10 years. It was led by SWOG, an international network of research institutions. The significance of the results, adding months if not years to the lives of many men, means every physician with prostate cancer patients should take them into account, Dr. Thompson said.


'/>"/>

Contact: Elizabeth Allen
allenea@uthscsa.edu
210-450-2020
University of Texas Health Science Center at San Antonio
Source:Eurekalert

Related medicine news :

1. New drug prevents spread of human prostate cancer cells
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
4. Study examines adverse effects among different radiation therapies for prostate cancer
5. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
6. Warren Buffett Has Early Stage Prostate Cancer
7. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
8. PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
9. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
10. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
11. Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... PITTSBURGH, Pa. (PRWEB) , ... October 13, 2017 , ... ... the dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a ... access to medication in darkness or restricted lighting. As such, it eliminates the need ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes ... of the facility as part of a disaster drill on October 3rd. , Apple ... Shelton City Emergency Manager, as well as the Connecticut Long Term Care Mutual ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
Breaking Medicine Technology: